Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12943898 | 0.92 | PTPRB (0.53) | PTPRB | |
| SCHEMBL10203120 | 0.89 | PTPRB (0.50) | PTPRB | |
| SCHEMBL10263752 | 0.89 | PTPRB (0.50) | PTPRB | |
| SCHEMBL500277 | 0.89 | PTPRB (0.59) | PTPRB | |
| SCHEMBL500276 | 0.89 | PTPRB (0.59) | PTPRB | |
| SCHEMBL468055 | 0.83 | PTPRB (0.54) | PTPRB | |
| SCHEMBL29794281 | 0.83 | PTPRB (0.54) | PTPRB | |
| SCHEMBL468060 | 0.83 | PTPRB (0.54) | PTPRB | |
| SCHEMBL683498 | 0.82 | PTPRB (0.51) | PTPRB | |
| SCHEMBL500135 | 0.80 | PTPRB (0.67) | PTPRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569348-B2 | Compounds, compositions, and methods for preventing metastasis of cancer cells | AERPIO THERAPEUTICS INC. (US) | 2013-10-29 | — | — | US | claimed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-07-02 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| WO-2011005330-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AKEBIA THERAPEUTICS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207730-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | PTPRB 1894/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | PTPRB 551/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | PTPRB 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.